NRGN and Alzheimer disease: Furthermore, CSF neurogranin levels projected future cognitive impairment (adjusted HR: 1.89; 95% CI: 1.29–2.78) in controls with normal cognitive function and predicted a decline in cognition in patients with symptomatic Alzheimer’s disease [262].